Protease inhibitor, patented in 1992 and approved for use in 1997.
Found 3 search result(s) for nelfinavir.
Agouron Pharmaceuticals
(HIV/AIDS Research: Its History & Future Meeting)
... 1999, which itself was acquired by Pfizer in 2000. Agouron codeveloped the protease inhibitor nelfinavir
Feb 23, 2021
... 1999, which itself was acquired by Pfizer in 2000. Agouron codeveloped the protease inhibitor nelfinavir
Feb 23, 2021
8.1 John Mellors — MACS and Beyond: Epidemiology, Viremia and Pathogenesis
(HIV/AIDS Research: Its History & Future Meeting)
... rate 00:13:30 difference is likely due to the higher frequency of preexistence of nelfinavir resistance mutants, or to the poor adherence to nelfinavir. We also looked at NNRTI (nonnucleoside reversetranscriptase inhibitor) based regimens, and there was no difference ...
Apr 27, 2021
... rate 00:13:30 difference is likely due to the higher frequency of preexistence of nelfinavir resistance mutants, or to the poor adherence to nelfinavir. We also looked at NNRTI (nonnucleoside reversetranscriptase inhibitor) based regimens, and there was no difference ...
Apr 27, 2021
8.2 David Ho — Unraveling of HIV Dynamics In Vivo
(HIV/AIDS Research: Its History & Future Meeting)
... inhibitor. There was indinavir 00:21:00 done with Emilio Emini, who's in the audience. There was nelfinavir done with the company Agouron, which I'm sure it has been absorbed by one ...
Apr 27, 2021
... inhibitor. There was indinavir 00:21:00 done with Emilio Emini, who's in the audience. There was nelfinavir done with the company Agouron, which I'm sure it has been absorbed by one ...
Apr 27, 2021